Launch of Aurigon GmbH, International Headquarters, in Munich Germany and successful transfer of operations from Aurigon Life Science to ATRC Aurigon Toxicological Research Center near Budapest in Hungary.
The management of Aurigon announces the completion of a successful major investment by an US/German Private Equity Group and additional grants acquisition.
As a result, strategically restructuring and material investment processes were successfully implemented, securing a broad spectrum of state of the art services for our customers and a continuous development and growth:
- expansion of the modern rodent facility at ATRC
- implementation of additional laboratory services at ATRC
ATRC will be supported by the Munich headquarters with business development activities and additional quality assurance and scientific expertise.